@article{74f836cd97f44ac0991f0a3947732b7e,
title = "Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease",
keywords = "Biologic Therapy, COVID-19, IBD, SARS-CoV-2",
author = "\{Jill Roberts Center Study Group Study Group\} and \{Weill Cornell Medicine-Gastrointestinal Study Group\} and Lukin, \{Dana J.\} and Anand Kumar and Kaveh Hajifathalian and Sharaiha, \{Reem Z.\} and Scherl, \{Ellen J.\} and Longman, \{Randy S.\} and Gabriela Funez-dePagnier and Lucia Duenas-Bianchi and Vinita Jacob and Battat, \{Robert J.\} and Tibor Krisko and Fortune, \{Brett E.\}",
note = "Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda. E. J. Scherl received grant support from AbbVie, AstraZeneca, Crohn's and Colitis Foundation, Janssen, New York Crohn's Foundation, Pfizer, UCB, Genentech, Seres Therapeutics, and Celgene, consulting fees from AbbVie, Abgenomics, Crohn's and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts. Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda . E. J. Scherl received grant support from AbbVie , AstraZeneca , Crohn{\textquoteright}s and Colitis Foundation , Janssen , New York Crohn{\textquoteright}s Foundation , Pfizer , UCB, Genentech , Seres Therapeutics, and Celgene , consulting fees from AbbVie, Abgenomics, Crohn{\textquoteright}s and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts. ",
year = "2020",
month = oct,
doi = "10.1053/j.gastro.2020.05.066",
language = "English",
volume = "159",
pages = "1541--1544.e2",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders",
number = "4",
}